What makes SARS-CoV-2 unique? Focusing on the spike protein

被引:6
作者
Qian, Jingbo [1 ,2 ]
Zhang, Shichang [3 ]
Wang, Fang [1 ,2 ]
Li, Jinming [4 ,5 ,6 ]
Zhang, Jiexin [1 ,2 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Lab Med, Nanjing, Peoples R China
[2] Branch Natl Clin Res Ctr Lab Med, Nanjing, Peoples R China
[3] Southern Med Univ, Shenzhen Hosp, Dept Clin Lab Med, Shenzhen, Peoples R China
[4] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Natl Ctr Gerontol,Natl Ctr Clin Labs, Beijing, Peoples R China
[5] Chinese Acad Med Sci & Peking Union Med Coll, Natl Ctr Clin Labs, Beijing, Peoples R China
[6] Beijing Hosp, Beijing Engn Res Ctr Lab Med, Beijing, Peoples R China
关键词
COVID-19; Omicron; SARS-CoV-2; spike protein; vaccines; variants; NEUTRALIZING ANTIBODIES; EFFICIENT REPLICATION; COVID-19; VACCINE; VARIANT; INFECTION; BINDING; EVASION; FUSION; IMMUNOGENICITY; VACCINATIONS;
D O I
10.1002/cbin.12130
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) seriously threatens public health and safety. Genetic variants determine the expression of SARS-CoV-2 structural proteins, which are associated with enhanced transmissibility, enhanced virulence, and immune escape. Vaccination is encouraged as a public health intervention, and different types of vaccines are used worldwide. However, new variants continue to emerge, especially the Omicron complex, and the neutralizing antibody responses are diminished significantly. In this review, we outlined the uniqueness of SARS-CoV-2 from three perspectives. First, we described the detailed structure of the spike (S) protein, which is highly susceptible to mutations and contributes to the distinct infection cycle of the virus. Second, we systematically summarized the immunoglobulin G epitopes of SARS-CoV-2 and highlighted the central role of the nonconserved regions of the S protein in adaptive immune escape. Third, we provided an overview of the vaccines targeting the S protein and discussed the impact of the nonconserved regions on vaccine effectiveness. The characterization and identification of the structure and genomic organization of SARS-CoV-2 will help elucidate its mechanisms of viral mutation and infection and provide a basis for the selection of optimal treatments. The leaps in advancements regarding improved diagnosis, targeted vaccines and therapeutic remedies provide sound evidence showing that scientific understanding, research, and technology evolved at the pace of the pandemic.
引用
收藏
页码:404 / 430
页数:27
相关论文
共 216 条
[11]  
[Anonymous], Different types of COVID-19 vaccines: How they work - Mayo Clinic
[12]  
[Anonymous], WHO Coronavirus (COVID-19.) Dashboard| WHO Coronavirus (COVID-19) Dashboard With Vaccination Data
[13]  
[Anonymous], COVID-19 Vaccine Tracker
[14]  
[Anonymous], ALPH OM EV YOU NEED
[15]  
[Anonymous], The effects of virus variants on COVID-19 vaccines
[16]  
[Anonymous], BIV SARS COV 2 MRNA
[17]   COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study) [J].
Arashiro, Takeshi ;
Arima, Yuzo ;
Muraoka, Hirokazu ;
Sato, Akihiro ;
Oba, Kunihiro ;
Uehara, Yuki ;
Arioka, Hiroko ;
Yanai, Hideki ;
Kuramochi, Jin ;
Ihara, Genei ;
Chubachi, Kumi ;
Yanagisawa, Naoki ;
Nagura, Yoshito ;
Kato, Yasuyuki ;
Ueda, Akihiro ;
Numata, Akira ;
Kato, Hideaki ;
Ishii, Koji ;
Ooki, Takao ;
Oka, Hideaki ;
Nishida, Yusuke ;
Stucky, Ashley ;
Smith, Chris ;
Hibberd, Martin ;
Ariyoshi, Koya ;
Suzuki, Motoi .
CLINICAL INFECTIOUS DISEASES, 2023, 76 (03) :E108-E115
[18]   BNT162b2 Vaccine Booster and Mortality Due to Covid-19 [J].
Arbel, Ronen ;
Hammerman, Ariel ;
Sergienko, Ruslan ;
Friger, Michael ;
Peretz, Alon ;
Netzer, Doron ;
Yaron, Shlomit .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (26) :2413-2420
[19]   The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds [J].
Baez-Santos, Yahira M. ;
St John, Sarah E. ;
Mesecar, Andrew D. .
ANTIVIRAL RESEARCH, 2015, 115 :21-38
[20]  
Balakrishnan VS, 2020, LANCET INFECT DIS, V20, P1128, DOI 10.1016/S1473-3099(20)30709-X